TheRightDoctors Logo
Pre Alpha
Insights from the World's Best Medical Minds
nine

Pause
Love It
Download

Dr. JPS Sawhney

Chairman, Dept. of Cardiology

Sir Ganga Ram Hospital, New Delhi


If we treat the risk factors adequately like for hypertension, diabetes, dyslipidemia and take control of all the bad risk factors like smoking and excessive alcohol, then we can prevent the onset of heart failure in the society adequately in time. So for that risk factor management is very essential

Mail us at editorial@therightdoctors.com. Stay updated on Facebook , Twitter , You Tube and LinkedIn.


Dr. JPS Sawhney

</b> Today, I am going to discuss about a new molecule called ARNI angiotensin receptor-neprilysin inhibitor, a new drug for the management of reduce congestive heart failure patients. This drug has been approved by FDA and is named Entresto marketed by Novartis. Now this drug has been incorporated in the management of congestive heart failure by both the European Society of Cardiology guidelines for heart failure management and also recently in this year only by ACC focused update on the management of heart failure. We have been treating patients with heart failure with decongestive treatment using diuretics and the adequate doses of the beta blockers and the RAS blockade. When in spite of these adequate doses, a lot of patients they continue to have the congestive heart failure symptoms or symptoms are not improving. In that situation that this new drug has been positioned. Now this is the drug which is besides the (01



  • Heart attack
  • STEMI
  • Primary PCI
  • Angioplasty
  • Heart Failure
  • ECHO

Join TheRightDoctors on WhatsApp. Type "JOIN" and send to 9676401536